DDB2 represses epithelial-to-mesenchymal transition and sensitizes pancreatic ductal adenocarcinoma cells to chemotherapy

202225 citationsJournal Articlegold Open Access

Authors

Julie Dardare · Institut de Cancérologie de Lorraine

Andréa Witz · Institut de Cancérologie de Lorraine

Margaux Betz · Centre National de la Recherche Scientifique

Aurélie François · Centre de Recherche en Automatique de Nancy

Morgane Meras · Institut de Cancérologie de Lorraine

Laureline Lamy · Centre de Recherche en Automatique de Nancy

Aurélien Lambert

Abstract

Our study highlights the potential tumor suppressive effects of DDB2 on PDAC progression. DDB2 could thus represent a promising therapeutic target or biomarker for defining prognosis and predicting chemotherapy response in patients with PDAC.

Topics & Keywords

Pancreatic and Hepatic Oncology Research Epigenetics and DNA Methylation Cancer Cells and Metastasis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Frontiers in Oncology

Volume 12, pp. 1052163-1052163

DOI: 10.3389/fonc.2022.1052163

Field-Weighted Citation Impact: 2.51